Literature DB >> 11849670

Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels.

Libor Vítek1, Milan Jirsa, Marie Brodanová, Milan Kalab, Zdenek Marecek, Vilém Danzig, Ladislav Novotný, Petr Kotal.   

Abstract

BACKGROUND: Oxidation processes play an important role in atherogenesis. Bilirubin IXalpha is recognised as a potent antioxidant. In the present study, we assessed the role of elevated serum bilirubin levels in the prevention of ischemic heart disease (IHD).
METHODS: The occurrence of IHD was determined in Gilbert syndrome (GS) patients above 40 years (n=50). The diagnosis was based on past medical history and ECG criteria. The occurrence was related to that of the comparable general population (n=2296). Serum biochemistry, including the total antioxidant status was evaluated in the GS subjects, IHD patients (n=38) and control subjects (n=38).
RESULTS: The prevalence of IHD in GS subjects (aged 49.7+/-9.0 years) was 2% (0.05-10.7%, 95% confidence interval), compared to 12.1% in a general population (P<0.05). Bilirubin, total antioxidant capacity and high density lipoprotein (HDL) cholesterol were found to be significantly higher in GS subjects compared to control groups (P<0.05). According to linear discriminant analysis, hyperbilirubinemia rather than elevation of HDL cholesterol levels seemed to be more important in protection from IHD.
CONCLUSIONS: In the present study, low prevalence of IHD in GS subjects was detected. It may be presumed that chronic hyperbilirubinemia prevent the development of IHD by increasing the serum antioxidant capacity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849670     DOI: 10.1016/s0021-9150(01)00601-3

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  112 in total

Review 1.  Gilbert syndrome.

Authors:  Andrew Fretzayas; Maria Moustaki; Olga Liapi; Themistocles Karpathios
Journal:  Eur J Pediatr       Date:  2011-12-09       Impact factor: 3.183

2.  Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.

Authors:  Cheryl McDonald; Jonathan Uy; Wenhua Hu; Victoria Wirtz; Salome Juethner; David Butcher; Donnie McGrath; Awny Farajallah; Graeme Moyle
Journal:  AIDS Patient Care STDS       Date:  2012-03-09       Impact factor: 5.078

3.  Preservation solution supplemented with biliverdin prevents lung cold ischaemia/reperfusion injury.

Authors:  Ryujiro Sugimoto; Yugo Tanaka; Kentaro Noda; Tomohiro Kawamura; Yoshiya Toyoda; Timothy R Billiar; Kenneth R McCurry; Atsunori Nakao
Journal:  Eur J Cardiothorac Surg       Date:  2012-05-30       Impact factor: 4.191

4.  Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.

Authors:  Heidi M Crane; Robin M Nance; Susan R Heckbert; Corey Ritchings; Lisa Rosenblatt; Matthew Budoff; Brian R Wood; David L Tirschwell; H Nina Kim; William C Mathews; Elvin Geng; Richard D Moore; Peter W Hunt; Joseph J Eron; Greer A Burkholder; Daniel R Drozd; Felicia C Chow; Kyra J Becker; Joseph R Zunt; Emily L Ho; Rizwan Kalani; Andrew Huffer; Bridget M Whitney; Michael S Saag; Mari M Kitahata; Joseph A C Delaney
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

5.  Heme oxygenase system in hepatic ischemia-reperfusion injury.

Authors:  James A Richards; Stephen J Wigmore; Luke R Devey
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

Review 6.  Bilirubin in the Liver-Gut Signaling Axis.

Authors:  Abdul-Rizaq Hamoud; Lauren Weaver; David E Stec; Terry D Hinds
Journal:  Trends Endocrinol Metab       Date:  2018-02-03       Impact factor: 12.015

Review 7.  Heme Oxygenase-1 in Kidney Health and Disease.

Authors:  Jeremie M Lever; Ravindra Boddu; James F George; Anupam Agarwal
Journal:  Antioxid Redox Signal       Date:  2016-05-26       Impact factor: 8.401

8.  Bilirubin Links Heme Metabolism to Neuroprotection by Scavenging Superoxide.

Authors:  Chirag Vasavda; Ruchita Kothari; Adarsha P Malla; Robert Tokhunts; Anthony Lin; Ming Ji; Cristina Ricco; Risheng Xu; Harry G Saavedra; Juan I Sbodio; Adele M Snowman; Lauren Albacarys; Lynda Hester; Thomas W Sedlak; Bindu D Paul; Solomon H Snyder
Journal:  Cell Chem Biol       Date:  2019-07-25       Impact factor: 8.116

9.  Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  K H Chan; R L O'Connell; D R Sullivan; L S Hoffmann; K Rajamani; M Whiting; M W Donoghoe; M Vanhala; A Hamer; B Yu; R Stocker; M K C Ng; A C Keech
Journal:  Diabetologia       Date:  2013-01-17       Impact factor: 10.122

10.  Does bilirubin prevent hepatic steatosis through activation of the PPARα nuclear receptor?

Authors:  Terry D Hinds; Samuel O Adeosun; Abdulhadi A Alamodi; David E Stec
Journal:  Med Hypotheses       Date:  2016-08-31       Impact factor: 1.538

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.